2nd Oct 2020 12:00
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Preliminary report published by Ulster University
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the publication of the preliminary report of an independent evaluation of Abc-19TM by Ulster University.
The independent report compares three commercially available immunoassays to evaluate performance metrics for the AbC-19TM lateral flow test, which is developed by the UK-RTC. The report notes the lack of a well-accepted gold standard assay against which to measure any newly developed immunoassay designed to detect antibodies to SARS-CoV-2.
To overcome these challenges, a 'pseudo gold standard' system was established against which to analyse the sensitivity and specificity of each of the three commercially available immunoassays using a well characterised serology sample set to evaluate performance metrics for the AbC-19TM test. Using the 'pseudo gold standard' system the report concludes that the UK-RTC AbC-19 lateral flow immunoassay shows a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%).
A link to the preliminary report can be found here:
https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v1
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Edward Whiley (Corporate Finance) | |
Alice Lane (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Related Shares:
ODX.L